Last updated July 18, 2026
Key finding
Pregabalin 300 mg/day significantly reduced mean pain scores versus placebo (P < 0.0001).
This study evaluated the efficacy of pregabalin in treating painful diabetic peripheral neuropathy. Higher doses of pregabalin (300 mg and 600 mg) significantly reduced pain scores compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy of pregabalin in treating painful diabetic peripheral neuropathy. Higher doses of pregabalin (300 mg and 600 mg) significantly reduced pain scores compared to placebo.
These findings are significant for clinicians treating patients with painful diabetic peripheral neuropathy, as they highlight the importance of dose selection in achieving effective pain relief. Understanding that higher doses of pregabalin can lead to meaningful improvements in pain management may help guide treatment decisions and enhance patient quality of life.
Limited generalizability due to specific population characteristics. Potential for unmeasured confounders affecting outcomes. Short duration of follow-up may not capture long-term effects.
Published in
Publication details and source links for this paper.
Ashish B, Gordon S, Chris W, et al. Pregabalin for Painful Diabetic Peripheral Neuropathy: A Pooled Analysis of Efficacy. Journal of Diabetes Investigation. 2026;17(5):827-834. doi:10.1111/jdi.70288
Pregabalin 300 mg/day significantly reduced mean pain scores versus placebo (P < 0.0001).
Pregabalin 600 mg/day significantly reduced mean pain scores versus placebo (P < 0.0001).
Pain reduction in HbA1c ≤ 8% was -1.69 for the 300 mg/day group (P < 0.0001).
Pain reduction in HbA1c > 8% was -1.04 for the 300 mg/day group (P ≤ 0.001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Pregabalin 150 mg/day, Pregabalin 300 mg/day, Pregabalin 75 mg/day, and 1 more and Mean pain score reduction compared to placebo (Pregabalin 150 mg/day), Mean pain score reduction with Pregabalin 300 mg/day, Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 300 mg/day, and 3 more.
This study contributes evidence to
Primary intervention
Pregabalin 150 mg/day
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
7
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Pregabalin 150 mg/day → Mean pain score reduction compared to placebo (Pregabalin 150 mg/day)
Pregabalin 150 mg/day → Mean pain score reduction compared to placebo (Pregabalin 150 mg/day)
Pregabalin 300 mg/day → Mean pain score reduction with Pregabalin 300 mg/day
Pregabalin 300 mg/day → Mean pain score reduction with Pregabalin 300 mg/day
Pregabalin 300 mg/day → Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 300 mg/day
Pregabalin 300 mg/day → Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 300 mg/day
Pregabalin 75 mg/day → Mean pain score reduction compared to placebo (Pregabalin 75 mg/day)
Pregabalin 75 mg/day → Mean pain score reduction compared to placebo (Pregabalin 75 mg/day)
Pregabalin 75 mg/day → Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 300 mg/day
Pregabalin 75 mg/day → Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 300 mg/day
Resmetirom (100 mg) → Mean pain score reduction with Pregabalin 600 mg/day
Resmetirom (100 mg) → Mean pain score reduction with Pregabalin 600 mg/day
Resmetirom (100 mg) → Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 600 mg/day
Resmetirom (100 mg) → Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 600 mg/day
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Pregabalin 150 mg/day and Mean pain score reduction compared to placebo (Pregabalin 150 mg/day), Pregabalin 300 mg/day and Mean pain score reduction with Pregabalin 300 mg/day.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Mean pain score reduction compared to placebo (Pregabalin 150 mg/day)
Measures Mean pain score reduction compared to placebo (Pregabalin 150 mg/day) as a key outcome.
All studies measuring Mean pain score reduction with Pregabalin 300 mg/day
Measures Mean pain score reduction with Pregabalin 300 mg/day as a key outcome.
All studies on Pregabalin 150 mg/day
Contributes to Pregabalin 150 mg/day evidence base.
All studies on Pregabalin 300 mg/day
Contributes to Pregabalin 300 mg/day evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Pregabalin 300 mg/day appears to improve Mean pain score reduction with Pregabalin 300 mg/day.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Mean pain score reduction with Pregabalin 300 mg/day
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Pregabalin 300 mg/day appears to improve Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 300 mg/day.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 300 mg/day
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Pregabalin 75 mg/day appears to improve Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 300 mg/day.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Pain reduction in patients with HbA1c ≤ 8% due to Pregabalin 300 mg/day
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Resmetirom (100 mg) appears to improve Mean pain score reduction with Pregabalin 600 mg/day.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Mean pain score reduction with Pregabalin 600 mg/day
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
